

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 18, No. 2

January 25th, 2019

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- CMS opens 2018 MIPS data submission
- AB1753 requires new prescription pads
- *Best of SABCS San Francisco*
- *Multidisciplinary Management of Cancers*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts)

Members. The next regular *ANCO FAX News* will be published on February 8th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

In separate comment letters to CMS, ASCO and ASH have urged the agency to ensure that every Medicaid enrollee with cancer can access the high-quality care needed to treat their disease. The comments were submitted in response to a proposed rule on Medicaid and the *Children's Health Insurance Program (CHIP) Managed Care* that aims to streamline the Program's regulatory requirements, reduce administrative burdens, and increase flexibility for state governments. Read ASCO's letter at www.asco.org/sites/new-www.asco.org/files/content-files/Comments-CMS-MMC-Jan-2019.pdf; read ASH's comments at www.hematology.org/Advocacy/Testimony.aspx.

Effective January 1st, Medicare is instituting new opioid prescribing policies that will impact Medicare Part D beneficiaries with a prescription drug benefit and their prescribers. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-medicare-part-d-opioid-prescribing-policies-2019.

ASCO, ASH, and COA have provided feedback to CMS on the *Administration's* continuing efforts to address the cost of prescription drugs, specifically its proposed pilot program to benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients. Their feedback highlighted the role physicians play in assuring the most appropriate utilization of cancer drug treatments and

cautioned against implementing any strategies to contain costs that may limit patient access to care. Specifically, ASCO opposes mandatory participation in a revived and revised *Competitive Acquisition Program (CAP)* demonstration project. Read ASCO's feedback at www.asco.org/sites/new-www.asco.org/files/content-files/IPI-ASCO-comments-Dec.2018.pdf; read ASH's comments at www.hematology.org/Advocacy/Testimony.aspx; and, read COA's comments at www.communityoncology.org/coa-formal-comments-on-international-pricing-index-model-for-medicare-part-b-drugs/.

CMS opened the data submission period for MIPS eligible clinicians who participated in Year 2 (2018) of the QPP. Data can be submitted and updated any time from January 2nd to April 2nd, with two exceptions—CMS Web Interface users need to report their quality performance category data between January 22nd and March 22nd; clinicians who reported quality measures via Medicare Part B claims throughout the 2018 performance year will have their quality data sent to CMS by their MAC. Submit your 2018 MIPS data by visiting the QPP website at qpp.cms.gov/login?. In addition, the QOPI Reporting Registry, a QCDR brought to you by ASCO and ASTRO, is your one-stop shop for 2019 MIPS reporting. Learn more at practice.asco.org/quality-improvement/quality-programs/qopi-reporting-registry?.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

The Global Challenge to Prevent Breast Cancer is a competition designed to surface

game-changing breast cancer prevention research ideas. The *Challenge*, sponsored by the *California Breast Cancer Research Program* (CBCRP), aims to advance breast cancer primary prevention by surfacing innovative breast cancer prevention research ideas from researchers and others interested in breast cancer prevention. By providing cash prizes, feedback from respected researchers, and the opportunity to present ideas to prominent leaders in the field, the *Challenge* aims to surface breakthrough ideas that will help catalyze the field of breast cancer primary prevention research. The most promising ideas will frame CBCRP's future funding strategy and will be further developed in California with \$15 million in grant funding from the *Program*. **The deadline for applications has been extended to January 31st.** For further information, visit topreventbreastcancer.org or contact Nicholas J. Anthis, *Program Officer, Environmental Health & Health Policy, California Breast Cancer Research Program, University of California, Office of the President*, at nicholas.anthis@ucop.edu.

The Controlled Substance Review Utilization and Evaluation System (CURES), California's prescription drug monitoring database, is now in effect and physicians must consult CURES prior to writing specified prescriptions. Learn more and access CMA's CURES resources at www.cmanet.org/news/detail/?article=doj-certifies-cures-physicians-must-check. The CMA/DOJ webcast on CURES is available for on-demand viewing at www.cmadocs.org/newsroom/news/view/ArticleId/27813/CURES-webinar-with-DOJ-now-available-for-on-demand-viewing.

Effective January 1st, a new California law (AB1753) took effect that requires all security prescription forms to have a uniquely serialized number. The legislation

did not include any transition or grandfathering period to allow for continued use of old controlled substance security prescription forms on or after January 1st. For more information, including answers to frequently asked questions about the implementation of this new law, visit www.mbc.ca.gov/Licensees/Prescribing/AB1753JointStatement.pdf.

California's AB2760, effective January 1st, requires that, for certain categories of high-risk patients, prescribers must offer a prescription of naloxone or another drug Federally approved for the complete or partial reversal of opioid overdose. It also requires the prescriber to provide specified education to those patients on overdose prevention and provide education about how naloxone or other FDA-approved drugs may be used to prevent an overdose.

The California Medical Association (CMA) has published a summary of the most significant new health laws of interest to physicians. For more details, see *Significant New California Laws of Interest to Physicians for 2019* at www.cmadocs.org/Portals/CMA/files/public/New%20California%20Health%20Laws%202019.pdf.

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the California Medical Association (CMA).** While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you. The CMA's *Center for Economic Services (CES)* has a team

of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers. For membership, please call (916) 551-2042; for reimbursement assistance, please call CMA's *Reimbursement Helpline* at (888) 401-5911.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—New Medicare Card Mailing Complete, 58% of Claims Submitted with MBI; Hospice Quality Reporting Program: Quality Measures User's Manual; Qualified Medicare Beneficiary Billing Requirements; Hospice Election Statements Lack Required Information or Have Other Vulnerabilities-Reminder; New Medicare Card: Web Updates; CDC Opioids Training Modules; Open Payments Data Update; Reporting Changes in Ownership-Reminder
- Events*—New Electronic System for Provider Reimbursement Review Board Appeals Call-February 5; New Part D Opioid Overutilization Policies Call-February 14
- Publications*—2019 DMEPOS HCPCS Code Jurisdiction List MLN Matters Article-New; NCCI PTP Edits: Quarterly Update MLN Matters Article-New; Medicare Claims Processing Manual MLN Matters Article-New; Clinical Lab Fee Schedule: Medicare Travel Allowance Fees MLN Matters Article-New; New Waived Tests MLN Matters Article-New; ICD-10 and Other Coding Revisions to NCDs MLN Matters Article-Revised;

Local Coverage Determinations MLN Matters Article-Revised; Skilled Nursing Facility ABN MLN Matters Article-Revised; Remittance Advice: An Overview Booklet-Revised; Proof of Delivery Documentation Requirements MLN Matters Article-New; Appropriate Use Criteria for Advanced Diagnostic Imaging Fact Sheet-New; New MBI: Get It, Use It MLN Matters Article-Revised; ICD-10-CM, ICD-10-PCS, CPT, and HCPCS Code Sets Educational Tool-Reminder

- Chemotherapy Administration-R16
- ICD-10 and Other Coding Revisions to NCDs-Revised CR11005
- Additional Information Required for Coverage and Pricing for Category III CPT Codes-R6
- Clinical Laboratory Fee Schedule-Medicare Travel Allowance Fees for Collection of Specimens CR11146
- Quarterly Update to the NCCI PTP Edits, Version 25.1, Effective April 1, 2019 CR11126
- New Waived Tests CR11080
- Local Coverage Determinations (LCDs)-Revised CR10901
- Medicare Claims Process Manual, Chapter 30 Revision CR10848
- Skilled Nursing Facility Advance Beneficiary Notice of Non-Coverage (SNF ABN)-Revised CR10567
- Stereotactic Radiosurgery LCD-R5
- MolDX: Breast Cancer Index Genetic Assay-R3
- MolDX: Molecular Diagnostic Tests (MDT) LCD-R7 and R8
- MolDX: Oncotype DX AR-V7 Nucleus Detect Test for Men with Metastatic

Castrate Resistant Prostate Cancer
(MCRPC) Final LCD-Effective March 2,
2019

**Forthcoming Noridian/JEMAC
meetings/webinars/workshops include:**

- Provider Enrollment Supporting Documentation Webinar (February 13)
- Submitting Your Enrollment Online-Part 1 Webinar (I&A; February 27)
- PECOS Part 1: Full Overview of PECOS Webinar (March 13)
- PECOS Part 2: Full Overview of PECOS Webinar (March 27)
- Independent Diagnostic Testing Facility (IDTF) Enrollment Webinar (April 10)
- Medicare Part A/B Revalidation Webinar (April 24)
- Submitting Your Enrollment Online-Part 1 Webinar (I&A; May 29)
- Submitting Your Enrollment Online-Part 2 Webinar (PECOS; June 26)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

Best of SABCS San Francisco

ANCO, in association with the *Organizing Committee* of the *San Antonio Breast Cancer Symposium* and *Encore Medical Education*, will host the *Best of San Antonio Breast Cancer Symposium San Francisco (Best of SABCS San Francisco)* at *The Claremont Hotel* on Saturday morning, January 26th. Hope S. Rugo, M.D., *UC San Francisco*, is the *Regional Director* for *Best of SABCS San Francisco*. Learn more and register at www.bestofsabcs.com/best-of-sabcs-san-francisco/.

19th Multidisciplinary Management of Cancers: A Case-based Approach

The *19th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 15-17th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. The meeting announcement was mailed in mid-November; learn more, register, and arrange for housing at www.multicancers.org

Additional Education Meetings

January 26th
Blood Cancer Conference
Leukemia & Lymphoma Society
San Francisco
(<http://www.lls.org/blood-cancer-conference>)

February 5th
Progress in the Treatment of Follicular Lymphoma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

February 11th
Treatment Update on Liver Cancer and Managing the Cost of Care
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

February 14-16th
Genitourinary Cancers Symposium
ASCO
San Francisco
(<http://gucasym.org>)

February 21st
Update on Glioblastoma in Adults
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

February 28th-March 2nd
ASCO-SITC Clinical Immuno-Oncology Symposium
ASCO & Society for Immunotherapy of Cancer
San Francisco

(<http://immunosym.org>)

March 5th

Medical Update on Ovarian Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 7th

Update on Chronic Lymphocytic Leukemia (CLL)

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 15th

Upcoming Trends in Renal Cell Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 18th

Advances in the Treatment of Colorectal Cancer

CancerCare Connect Education Workshop

(www.cancercare.org/connect_workshops)

March 20th-22nd

45th Annual Meeting & Cancer Center Business Summit

ACCC

Washington, D.C.

([https://www.accc-cancer.org/home/attend/accc-](https://www.accc-cancer.org/home/attend/accc-45th-annual-meeting-cancer-center-business-summit?)

[45th-annual-meeting-cancer-center-business-summit?](https://www.accc-cancer.org/home/attend/accc-45th-annual-meeting-cancer-center-business-summit?))

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

ANCO Online

ANCO's website, www.anco-online.org, features a general description and introduction to the *Association*—its activities, leadership, and membership benefits; advocacy information (including ANCO and ASCO resources); clinical and professional education meeting announcements and distributed materials; survey reports and publications; clinical trials information; links to affiliated organizations; updated physician, nurse, manager, and patient

resources; and, updated Corporate Member drug reimbursement and patient assistance program information.

Board of Directors

The ANCO *Board of Directors* met on January 22nd to discuss and/or act upon the following:

- Open forum with Sustaining and Diamond Level Corporate Members
- 2018 *Annual Election* results
- Conflict of interest policy
- Nominations for *Secretary* and *Treasurer*
- FY2019 budget
- 2019 *Board* teleconference and meeting schedule

Contact the ANCO office for additional information on any of these items.

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for February 27th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current *Directory of Members* is available **online** at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and

benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi-Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Annadel Medical Group/St Joseph's Heritage Healthcare, Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care, and Palo Alto Medical Foundation* for their multi-site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

The *Stanford Cancer Center* is organizing a ***Review of the 60th Annual ASH Meeting*** on January 26th at The Ritz-Carlton in Half Moon Bay. Learn more at med.stanford.edu/cme/courses/2019/hem19_full.html.

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Adaptive Biotechnologies
Agios Pharmaceuticals*

*Alexion Pharmaceuticals • AMGEN
AMAG Pharmaceuticals • Array BioPharma
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Celgene • Clovis Oncology • Coherus Biosciences
Daiichi Sankyo • Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lexicon Pharmaceuticals
Lilly Oncology • Merck
Novartis Oncology • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Puma Biotechnology • Sandoz Biopharmaceuticals
Sanofi Genzyme • Seattle Genetics
Taiho Oncology • Takeda Oncology
Tempus Labs • TerSera Therapeutics • Tesaro
Teva Oncology • Verastem Oncology*

We especially wish to thank and welcome *Adaptive Biotechnologies, Heron Therapeutics, Tempus Labs, and Verastem Oncology* as new Corporate Members for 2019. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Adaptive Biotechnologies informs ANCO that its cloneSEQ Assay is now FDA-cleared and covered by Medicare for detecting and monitoring minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (ALL).

Exelixis informs ANCO that the *United States Food and Drug Administration* has approved Cabometyx for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Publications, Resources, Services, & Surveys

ANCO and MOASC jointly publish a weekly e-publication entitled *California Oncology Weekly*. The *Weekly* is e-mailed and FAXed to all current ANCO recipients of the *ANCO FAX News* and digests national, California, ANCO, MOASC, and industry news. Please send an e-mail to execdir@anco-online.org if you are not receiving the *Weekly* via e-mail or FAX.

The **ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice**. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date, and will continue to grow as more guidelines and tools are added. Download the app at www.asco.org/guidelines or www.asco.org/apps.

ASCO's Clinical Affairs Department provides services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO's Practice Consulting Services & Support offers personalized services to help practices achieve operational goals. Their team of nationally recognized consultants in oncology practice management is dedicated to assisting practices succeed in today's constantly evolving practice environment. Services include readiness assessment, practice operational assessment,

practice transformation implementation support, analytical services, triage pathways. For more information, read the article (featuring Peter Paul Yu, M.D., former ANCO and ASCO *President*) at connection.asco.org/magazine/features/asco-practice-consulting-services-and-support or visit practice.asco.org. **ASCO's Practice Engagement Program helps administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system.**

ASCO's Practice Central, a new website that serves as an online information hub to help oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. ASCO *Practice Central* offers oncology practices easy-to-access information, tools, and resources that are designed to foster effective business practices and support high-quality patient care. Bookmark ASCO *Practice Central* at practice.asco.org.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. A new video overview of PracticeNET explains how the network gives practices a unique opportunity to see how they compare to others and learn from their peers. Watch the video at www.youtube.com/watch?v=Qc3BgEsyxfo&feature=youtu.be&list=PLwVG_3RvChvHZn6e86LNy_Ie9eSbZvNff. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Learn more and enroll at www.asco.org/practice-guidelines/practice-support/practicenet?et_cid=39764896&et rid=933038345&linkid=Enroll+in+PracticeNET.

The January 2019 issue of ASCO's *Journal of Oncology Practice* (JOP) is available online and features articles entitled *Adaptation of Oncology Fellowship to Reflect Contemporary Practice*; *CancerLinQ: Cutting the Gordian Knot of Interoperability*; *Putting Integrative Oncology Into Practice: Concepts and Approaches*; *Advance Care Planning Among Patients With Advanced Cancer*. Visit ascopubs.org/toc/jop/current for more information.

A new assessment option for oncologists—called the ABIM/ASCO Medical Oncology: Learning & Assessment—will become available in 2020 and will take the place of ABIM's Knowledge Check-In in Medical Oncology. The Learning & Assessment is a flexible, lower stakes MOC program that offers physicians the choice of medical oncology assessments. Learn more at connection.asco.org/magazine/society-member-news/new-abimasco-moc-pathway-be-available-2020.

Data abstraction for ASCO's QOPI Round 1 opened on January 9th and will close on June 3rd. Round 1 final reports will be available approximately two weeks after the round closes. Learn more at practice.asco.org/quality-improvement/quality-programs/quality-oncology-practice-initiative?.

Managing the cost of cancer care can be overwhelming and ASCO Answers can help your patients. ASCO Answers gives your patients practical guidelines for managing the cost of their cancer care. It covers health insurance benefits, information about the Affordable Care Act, tips, resources, & more! Learn more and order ASCO Answers at shop.asco.org/mccc15_managing-the-cost-of-cancer-care-pack-of-50-booklets/?.

ACCC's 2019 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs

(PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/home/learn/publications/patient-assistance-and-reimbursement-guide to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for: acute myeloid leukemia (V1.2019), AIDS-related Kaposi sarcoma (V2.2019), B-cell lymphomas (V1.2019), bladder cancer (V1.2019), CLL/SLL (V2.2019), cervical cancer (V3.2019), cutaneous melanoma (V1.2019), genetic/familial high-risk assessment: breast and ovarian (V3.2019), Merkel cell carcinoma (V2.2019), non-small cell lung cancer (V3.2019), occult primary (cancer of unknown origin (CUP; V2.2019), systemic light chain amyloidosis (V1.2019), uterine neoplasms (V2.2019), vulvar cancer (V2.2019). Go to www.nccn.org for more information.

Individual Membership Dues for 2019

Membership renewal notices for 2019 were mailed to all members the last week in November. If you have not yet done so, then please return your 2019 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.